MA40848A - Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) - Google Patents
Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)Info
- Publication number
- MA40848A MA40848A MA040848A MA40848A MA40848A MA 40848 A MA40848 A MA 40848A MA 040848 A MA040848 A MA 040848A MA 40848 A MA40848 A MA 40848A MA 40848 A MA40848 A MA 40848A
- Authority
- MA
- Morocco
- Prior art keywords
- enhancer
- ezh2 inhibitors
- zeste homolog
- zeste
- homolog
- Prior art date
Links
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title 2
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069438P | 2014-10-28 | 2014-10-28 | |
| US201462075596P | 2014-11-05 | 2014-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40848A true MA40848A (fr) | 2021-05-05 |
Family
ID=54360465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040848A MA40848A (fr) | 2014-10-28 | 2015-10-28 | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170334891A1 (enExample) |
| EP (1) | EP3212639A1 (enExample) |
| JP (1) | JP6571180B2 (enExample) |
| KR (1) | KR20170068603A (enExample) |
| CN (1) | CN107148419A (enExample) |
| AU (1) | AU2015340614B2 (enExample) |
| BR (1) | BR112017008840A2 (enExample) |
| CA (1) | CA2965729A1 (enExample) |
| MA (1) | MA40848A (enExample) |
| RU (1) | RU2017118165A (enExample) |
| WO (1) | WO2016066697A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| MX2018013519A (es) * | 2016-05-05 | 2019-03-14 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homologo zeste 2. |
| AU2018210099A1 (en) | 2017-01-19 | 2019-08-15 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| SG11202009438UA (en) | 2018-04-18 | 2020-11-27 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| AU2020288563A1 (en) | 2019-06-05 | 2022-01-06 | Mirati Therapeutics, Inc. | Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| PH12022550188A1 (en) | 2019-07-24 | 2022-11-21 | Constellation Pharmaceuticals Inc | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| IL326442A (en) * | 2019-07-24 | 2026-04-01 | Constellation Pharmaceuticals Inc | EZH2 inhibition in combination therapies for cancer treatment |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8536179B2 (en) * | 2010-05-07 | 2013-09-17 | Glaxosmithkline Llc | Indoles |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| CA2854447A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| CA2862289C (en) * | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| US9505745B2 (en) * | 2013-04-30 | 2016-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| EP3019494B1 (en) * | 2013-07-10 | 2017-06-21 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
-
2015
- 2015-10-28 CN CN201580058856.7A patent/CN107148419A/zh active Pending
- 2015-10-28 JP JP2017522890A patent/JP6571180B2/ja not_active Expired - Fee Related
- 2015-10-28 MA MA040848A patent/MA40848A/fr unknown
- 2015-10-28 EP EP15786958.7A patent/EP3212639A1/en not_active Withdrawn
- 2015-10-28 CA CA2965729A patent/CA2965729A1/en not_active Abandoned
- 2015-10-28 US US15/522,373 patent/US20170334891A1/en not_active Abandoned
- 2015-10-28 KR KR1020177014034A patent/KR20170068603A/ko not_active Withdrawn
- 2015-10-28 WO PCT/EP2015/075009 patent/WO2016066697A1/en not_active Ceased
- 2015-10-28 AU AU2015340614A patent/AU2015340614B2/en not_active Ceased
- 2015-10-28 RU RU2017118165A patent/RU2017118165A/ru not_active Application Discontinuation
- 2015-10-28 BR BR112017008840A patent/BR112017008840A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6571180B2 (ja) | 2019-09-04 |
| JP2017532360A (ja) | 2017-11-02 |
| AU2015340614B2 (en) | 2018-07-19 |
| WO2016066697A1 (en) | 2016-05-06 |
| US20170334891A1 (en) | 2017-11-23 |
| CA2965729A1 (en) | 2016-05-06 |
| BR112017008840A2 (pt) | 2017-12-19 |
| RU2017118165A3 (enExample) | 2018-12-10 |
| KR20170068603A (ko) | 2017-06-19 |
| AU2015340614A1 (en) | 2017-05-18 |
| RU2017118165A (ru) | 2018-11-29 |
| EP3212639A1 (en) | 2017-09-06 |
| CN107148419A (zh) | 2017-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289448B1 (en) | Generation of peroxyformic acid through polyhydric alcohol formate | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| ZA201507398B (en) | Enhancer of zeste homolog 2 inhibitors | |
| HUE062158T2 (hu) | EZH2 inhibitorok a limfóma kezelésére | |
| IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
| HUE039869T2 (hu) | N-Azaspirocikloalkán helyettesített N-heteroaril vegyületek és készítmények az SHP2 aktivitás gátlására | |
| IL250262B (en) | Spirocyclic cathepsin c inhibitors | |
| LT3121175T (lt) | 1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| IL257061A (en) | Inhibitors of ezh2 | |
| BR112016021629A2 (pt) | inibidores de c5a para o tratamento de pneumonia viral | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| IL247334A0 (en) | Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy | |
| AU2017260854B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| IL249674B (en) | Quinolizinone derivatives as pi3k inhibitors | |
| HUE052088T2 (hu) | Neridronsav vagy sójának alkalmazása osteoarthrosis kezelésére | |
| TH1601000084A (th) | วิธีและองค์ประกอบของสูตรผสมแกรนูล | |
| TH1601002537A (th) | กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง | |
| TH1501006560A (th) | ตัวยับยั้งของเอนแฮนเซอร์ของเซสต์ฮอมอลอก 2 | |
| TH1601002217A (th) | กระบวนการสำหรับการเตรียมของสารยับยั้ง pde4 |